@BCOSCardioOnc

Our mission is to promote research, best clinical practice and a wider understanding of the effects of cancer treatment on the cardiovascular system.

 United Kingdom
bc-os.org/
Joined November 2016
  • Tweets173
  • Following213
  • Followers518
56Media
1
124
more replies
Please take 10 minutes to complete this short survey (forms.office.com/e/sA3Mzeev3…), which seeks to gain an overview of opinions from UK-based healthcare professionals in relation to cardio-oncology research priorities.
1
1
1
184
This will inform future discussions and funding applications for collaborative UK cardio-oncology research. For further information, please contact enquiries@bhfcrc.org.
1
1
173
The PROACT trial found adding enalapril to standard care during chemotherapy did not prevent cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy. Read more on the trial: bit.ly/3ZnZWiV #ACCLATAM
45
114
15,261
We are highlighting the sessions you can expect at BSEcho 2024 - we're excited to see you in Edinburgh! See the programme for our cardio-oncology session in association with @BCOSCardioOnc 👇 View the full programme and book on our website: ow.ly/PFpC50SZ6rA
Four talks: Cardio-oncology: What's the fuss about?, How to set up a service, Strain and its utility in cancer patients, MDT discussion

ALT Four talks: Cardio-oncology: What's the fuss about?, How to set up a service, Strain and its utility in cancer patients, MDT discussion

4
4
668
This joint @BritishCardioSo @BCOSCardioOnc and @UCLH Cancer Academy course will give the attendee an update in contemporary cardio-oncology practice and will cover recent updates in cardio-oncology. members.britishcardiovascula…
This joint British Cardiovascular Society, British Cardio-Oncology Society and University College London Hospitals Cancer Academy course will give the attendee an update in contemporary cardio-oncology practice and will cover recent updates in cardio-oncology. A multidisciplinary practical approach to common cardiac issues in oncology/haem-oncology patients will be explored. For the first time dedicated sessions for oncologists and for haematologists will be incorporated into the day.

ALT This joint British Cardiovascular Society, British Cardio-Oncology Society and University College London Hospitals Cancer Academy course will give the attendee an update in contemporary cardio-oncology practice and will cover recent updates in cardio-oncology. A multidisciplinary practical approach to common cardiac issues in oncology/haem-oncology patients will be explored. For the first time dedicated sessions for oncologists and for haematologists will be incorporated into the day.

1
11
29
1,322
#GCOS2024 is going to be packed with talks from leading voices around the world including @BlaesAnneMD, Dr Alexander Lyon, Dr Bonnie Ky, and many more. See the Full Lineup: gcos2024.com/agenda Don't miss out - save your spot: gcos2024.com/registration #cardioonc
8
1
15
1,738
In this #JACCCardioOnc review, Dr. @DavidGGent, et al cover the breadth of what is known about #CVD in the adult #HCT population, focusing on acute & late complications, risk prediction, surveillance, & treatment of complications. bit.ly/3ZeW97w #CardioOnc
10
19
4,169
Food for thought. Are the historical anthracycline conversion ratios still appropriate for use in contemporary clinical practice and research? jamanetwork.com/journals/jam…

Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset...

This multicenter cohort study pools data from more than 28 000 children with cancer who had survived 5 or more years to evaluate the optimal dose equivalence ratio for late-onset cardiomyopathy...

jamanetwork.com
1
3
245
A selection of the 10 best cardio-oncology papers this year (in no particular order...)🎁🎄🎅 @CircAHA @escardio @ehj_ed @JACCJournals @NatureMedicine @JAMA_current @ICOSociety @CD_AACR @ACPUK @BritSocHaem @TheBHF
1
17
3
28
4,692
more replies
10. Biomarkers and cardiovascular outcomes in CAR T-cell therapy recipients ❓Multi-centre registry study examining the association between CAR-T related severe CV events (SCE) and mortality. 🏥202 patients w/ anti-CD19 CAR-T, median f/u 297 days. academic.oup.com/eurheartj/a…

Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients

AbstractAims. Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient’s immune system to target cancer. There are sparse existing data charact

academic.oup.com
1
2
245
SCE (HF, cardiogenic shock or MI) in 16% & ☠️ in 53% at last f/u. SCE associated w/ ⬆️ overall mortality (HR 2.8; 95% CI 1.6 - 4.7) and non-relapse mortality (HR 3.5; 95% CI 1.4 - 8.8). ☠️ associated w/ ⬆️ IL-6 and ferritin after CAR-T, SCE also associated w/ ⬆️ CRP & trop.
1
166
Load more